August 26th 2021, 1:00pm
German Hernandez, MD, FASN, FACP, and Ellen Ginzler, MD, MPH, discuss barriers to treatment access in lupus nephritis, and address future directions and unmet needs of the disease.
August 24th 2021, 1:00pm
German Hernandez, MD, FASN, FACP, and Ellen Ginzler, MD, MPH, provide insight into the FDA approved therapies for lupus nephritis, belimumab and voclosporin, including an overview of clinical evidence, mechanism of action, and patient selection.
August 19th 2021, 1:00pm
Rheumatology and nephrology experts provide an overview of the pharmacologic treatment options in lupus nephritis and discuss recent FDA approved therapies belimumab and voclosporin.
August 17th 2021, 1:00pm
Ellen Ginzler, MD, MPH, and German Hernandez, MD, FASN, FACP, discuss key drivers of healthcare utilization, progression of patients to end stage renal disease, and goals of treatment for lupus nephritis.
August 12th 2021, 1:00pm
Rheumatology and nephrology experts discuss monitoring of patients, renal flares, and consequences of progression in lupus nephritis.
August 10th 2021, 1:11pm
Ellen Ginzler, MD, MPH, and German Hernandez, MD, FASN, FACP, provide insight into the clinical presentation of patients with lupus nephritis, the progression of systemic lupus erythematosus to lupus nephritis, and the prevalence of this rare disease.
August 5th 2021, 1:49pm
Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, provide an overview of systemic lupus erythematosus and lupus nephritis.
January 29th 2021, 4:30pm
A 4-biomarker panel can help ensure rheumatoid arthritis (RA) is accurately diagnosed, according to study results published in Arthritis Research & Therapy.
January 25th 2021, 10:12pm
Voclosporin, the first FDA-approved oral therapy for lupus nephritis, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.
January 23rd 2021, 11:45am
Patients with rheumatoid arthritis (RA) were asked their preferences of second-line treatment options such as biologics and Janus kinase inhibitors, taking into account such factors as the probability of severe side effects, treatment effectiveness, administration route, and more.
